It further paves the way to exploit the CLR/glycan axis in the context of melanoma to design new therapeutic strategies exploiting DCs’ potentialities while avoiding hijacking by the tumor, to restore potent anti-tumor immunity and improve patient’s clinical outcome. Here, DCLK3 is linked to neoplasm.